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Background/Aims
Current therapy for gastroparesis with prokinetic agents is limited by options and side effects. One macrolide, erythromycin 
(ERY), is associated with possible sudden cardiac death from QT prolongation due to P450 iso-enzyme inhibition. An alter-
native, azithromycin (AZI), lacks P450 inhibition. We compared the effect on gastric emptying half-times (t½) between AZI and 
ERY in patients diagnosed with gastroparesis by gastric emptying scintigraphy.  
Methods
Patients stopped medications known to affect gastric emptying prior to the study, and then ingested 1 scrambled egg meal 
labeled with 18.5-37 MBq of technetium-99m sulfur colloid followed by continuous imaging for 120 minutes, at 1 minute per 
frame. A simple linear fit was applied to the rate of gastric emptying, and gastric emptying t½ was calculated (normal = 45-90 
minutes). At 75-80 minutes, if the stomach had clearly not emptied, patients were given either ERY (n = 60) or AZI (n = 
60) 250 mg IV and a new post-treatment gastric emptying t½ was calculated.
Results
Comparison of gastric emptying t½ showed a similar positive effect (mean gastric emptying t½ for AZI = 10.4 ± 7.2 minutes; 
mean gastric emptying t½ for ERY = 11.9 ± 8.4 minutes; p = 0.30).
Conclusions
AZI is equivalent to ERY in accelerating the gastric emptying of adult patients with gastroparesis. Given the longer duration 
of action, better side effect profile and lack of P450 interaction for AZI as compared with ERY, further research should eval-
uate the long term effectiveness and safety of AZI as a gastroparesis treatment.
(J Neurogastroenterol Motil 2010;16:407-413)
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Introduction
Gastroparesis (GP) or “delayed gastric emptying” is a chron-
ic gastrointestinal motility disorder of rising prevalence and 
cost.
1-7 GP results from the impaired transit of intraluminal con-
tents of the stomach into the duodenum in the absence of me-
chanical gastric outlet obstruction.
1 The most common etiologies 
of GP are diabetes, post-surgical, medication-induced, idiopathic 
or post-viral infection causing functional dyspepsia. These con-
ditions are part of a spectrum of clinical conditions, which range 
from the minimal delay of gastric emptying seen in functional 
dyspepsia to the profound delay caused by neurological dysfunc-
tion associated in long-standing diabetes.
2-17 Symptom presen-
tation in GP varies and can include early satiety, nausea and vom-
iting, abdominal pain, bloating and worsening gastroesophageal 
reflux. Moreover, GP patients are at significant risk for malnu-
trition due to severe weight loss from chronic nausea and vomit-
ing leading to increased healthcare costs from work days lost to 
multiple ED visits or hospitalizations for symptom manage-
ment.
2-17 Compared with hospital admissions for other upper gas-
trointestinal illnesses, GP patients typically have more co-mor-
bidities, undergo more inpatient procedures, experience a longer 
length of stay with higher total charges, and have an increased 
rate of inpatient death.
2 Given these trends, effective treatments 
for GP are increasingly important. 
Currently, erythromycin (ERY) is the most widely accepted 
and potent treatment for GP.
17,18 ERY is a macrolide antibiotic 
that accelerates gastric emptying to promote the dumping of food 
and undigested material from the stomach into the duodenum. 
The prokinetic effects of ERY are well documented and partially 
attributed to agonist effects on smooth muscle motilin recep-
tors.
19-23 ERY is the most potent prokinetic for treatment of GP 
symptoms such as nausea, vomiting and abdominal pain.
1,17,18 In 
fact, ERY is 30%-60% more effective in gastric emptying than 
other prokinetic agents, such as metoclopramide, cisapride and 
domperidone.
24
Despite the known benefits of ERY, a major problem is the 
association of this drug with an increased risk of cardiac arrhy-
thmias. First, both IV and oral ERY lead to an increased QT in-
terval reflecting prolongation of cardiac repolarization, predis-
posing patients to torsades de pointes and sudden cardiac 
death.
25-31 Second, ERY interacts with other drugs to increase the 
risk of cardiac arrhythmias. In one study, patients taking ERY 
exhibited a 2-fold increase in the adjusted rate of sudden cardiac 
death when compared with untreated patients.
25 The rate of sud-
den cardiac death was increased 5-fold in the presence of potent 
inhibitors of cytochrome P450 3A (CYP3A) isozymes, such as 
calcium channel blockers, statins and selective serotonin reuptake 
inhibitors. The proposed mechanism of these drugs is that the 
plasma level of ERY, a known substrate of CYP3A isozymes, is 
increased significantly upon CYP3A inhibition, resulting in an 
increased risk of serious cardiac arrhythmias. Unlike ERY how-
ever, azithromycin (AZI) does not interact with the CYP3A iso-
enzymes and is not involved in significant drug-drug interac-
tions.
32,33 The prior findings make ERY a less attractive option 
for many GP patients.  
Recently our group used antroduodenal manometry to show 
that AZI is promising as an alternative to ERY for treating GP.
1 
Here, we extend this finding by using provocative testing with 
gastric emptying scintigraphy, the gold standard for diagnosis of 
GP.
34 We hypothesized that both AZI and ERY are equivalent 
in improving the gastric emptying t½ in patients during the pro-
vocative phase of their gastric emptying scintigraphy (GES) due 
to the fact that both medications are motilin agonists and should 
act similarly to promote gastric emptying. 
Materials and Methods
1. Study design
This study is a retrospective case-control analysis of 120 pa-
tients who underwent GES with provocative testing at the 
University of Florida department of Nuclear Medicine from July 
to November 2009. Patients were evaluated for chronic abdomi-
nal pain or suspected GP. The research protocol was approved by 
the University of Florida Health Science Center Institutional 
Review Board. 
2. Data/patient selection
Consecutive patients with chronic abdominal pain or sus-
pected GP (n = 120) underwent GES performed as part of their 
diagnostic medical workup. All patients underwent a physical ex-
amination prior to GES to exclude any mechanical obstruction. 
None of the patients received narcotic analgesics for 48 hours pri-
or to the study. We excluded patients with a history of ob-
struction, psychiatric or eating disorders, a macrolide allergy or 
malignancy. In addition, patients with systemic diseases other 
than diabetes or collagen vascular diseases were also excluded. 
Once diagnosed with GP by GES, the patients received either IV Treating Gastroparesis With Azithromycin
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Table 1. Baseline Characteristics of the Azithromycin and Ery-
thromycin Groups
Azithromycin Erythromycin p-value
Age (mean ± SD, yr)   47 ± 17   48 ± 15 0.64
Males (n)   14   12 0.66
GES t½ prior to provocative 178 ± 77 166 ± 68 0.36
  testing (mean ± SD, min)
Diagnosis (n)
    Gastroesophageal reflux disease   24   30 0.28
    Irritable bowel syndrome     2     2 0.65
    Cirrhosis     5   13 0.04
    Hypothyroidism     9     7 0.41
    Chronic pancreatitis     2     5 0.25
    Diabetes   14   13 0.83
Patient symptoms (n)
    Chronic abdominal pain   38   31 0.20
    Nausea and vomiting   29   33 0.47
    Weight loss     2     3 0.65
    Abdominal distention/bloating   10   12 0.64
    Constipation     5     5 0.25
GES, gastric emptying scintigraphy.
ERY or IV AZI depending on the availability of the medication 
in the pharmacy for the provocative testing phase of GES.  
3. Gastric emptying scintigraphy technique
Patients stopped all medications known to affect gastric emp-
tying 48 hours prior to the study. Patients then underwent GES 
by consuming a meal of one whole scrambled egg (85 calories) 
with 2 pieces of white bread (133 calories)/1 pat of butter (36 
calories) and 50-100 cm
3 of water for a total calorie count of 254 
calories. The meal was labeled with 18.5-37 MBq of technetium- 
99m sulfur colloid. The imaging was performed using either a 
single-headed gamma camera, equipped with a low-energy high 
resolution collimator or a dual-headed camera. Both cameras 
were positioned in the left anterior oblique position to minimize 
the effects of varying gastric attenuation on the quantitation of the 
gastric emptying rate. Gastric emptying was followed by con-
tinuous imaging for 120 minutes at 1 minute per frame. We set a 
linear rate of emptying to the data from 0-75 minutes and ob-
tained an extrapolated half-time of emptying (normal t½ = 
45-90 minutes). Normal values for this meal and imaging meth-
odology were obtained by one of the authors using 60 normal vol-
unteers (age range: 26-60) in 1981-1982 at Henry Ford Hospital 
(WED personal communication, not published). Since gastric 
emptying follows zero order kinetics, the rate was effectively de-
termined prior to 75 minutes. Unless the stomach clearly emp-
tied, a prokinetic drug was given. All patients in our study were 
given either 250 mg of IV ERY (n = 60) or IV AZI (n = 60)  in-
fused over 20 minutes at 75-80 minutes with 15 minutes of fur-
ther imaging to determine the new post-drug gastric emptying 
half-time. AZI was utilized for provocative testing because its po-
tential prokinetic effects were already known, and there was a na-
tional shortage of IV ERY, such that IV ERY was simply 
unavailable. This switch to AZI was made for several months 
when IV ERY simply could not be obtained.
4. Statistical methods
The gastric emptying data obtained during from the provo-
cative testing were compared using a 2 tailed t test with SPSS 18 
software. All values are expressed as a mean ± SD. The null hy-
pothesis was constructed with the assumption that no significant 
difference would be seen between IV ERY and IV AZI in pa-
tients during the provocative phase of their GES.  
Results
Patients in the ERY and AZI groups were closely matched 
for baseline characteristics by age, gender, symptoms at pre-
sentation and diagnoses prior to the study (Table 1). In the ERY 
group, the mean age was 47 ± 17 years with an age range of 
21-71 years. In the AZI group, the mean age was 48 ± 15 years 
with an age range of 14-80 years. Symptoms on presentation in 
this group were similarly matched in number to the ERY group 
(Table 1). Prior surgeries in both these groups included orthoptic 
liver transplantation, cholecystectomy, umbilical hernia repair, 
Nissen fundoplication, gastric bypass, appendectomy, repair of a 
liver laceration and splenectomy. Statistical analysis showed no 
significant difference with the exception that cirrhotic patients 
were higher in number in the ERY group as compared to AZI. 
The gastric emptying t½ was similar for both groups with a mean 
gastric emptying t½ for ERY = 166 ± 68 minutes and a mean 
gastric emptying t½ for AZI = 178 ± 77 minutes. Gastric emp-
tying t½ in patients receiving either ERY or AZI showed a sim-
ilar positive effect with a mean gastric emptying t½ for AZI = 
10.4 ± 7.2 minutes and a mean gastric emptying t½ for ERY = 
11.9 ± 8.4 minutes. No significant difference was found between 
IV AZI and IV ERY for either group with a p = 0.30 (Fig. 2). 
No adverse or side effects were reported by either group during 
the provocative phase of our gastric emptying study.  Jean M Larson, et al
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Figure 1. Azithromycin (A) and ery-
thromycin (B) accelerated gastric em-
ptying as measured by gastric empty-
ing scintigraphy. Simple linear fits 
were applied to obtain the gastric em-
ptying t½ before and after provocative 
testing. GES, gastric emptying scinti-
graphy.
Discussion
The rising prevalence and cost of GP, as well as increasing 
evidence of cardiac arrhythmias and drug-drug interactions re-
lated to ERY has stimulated interest in developing new treat-
ments for GP. In addition, the recent FDA black box warning 
for tardive dyskinesia for metoclopramide makes the need for new 
alternatives for GP even more critical. As a result, we sought to 
study an alternative macrolide, AZI for possible treatment of GP 
patients. We found that ERY and AZI have a similar positive ef-
fect on gastric emptying t½ during the provocative testing phase 
of gastric emptying scintigraphy. This result supports the use of 
AZI as a viable alternative to ERY for treating GP, as well as 
findings from a previous study and case report suggesting a role 
for AZI in the treatment of GP.
35,36 AZI could also be used dur-
ing provocative testing with GES to evaluate response to this 
novel prokinetic that has never previously been used in the liter-
ature for such a purpose. 
Moreover, our study further expands on the recent findings 
from our institution with antroduodenal manometry which show-
ed that AZI stimulated antral motility in a manner similar to 
ERY, but with a longer duration of action for patients with 
chronic functional abdominal pain and GP.
1 Furthermore, our 
results have clinical significance for GP patients due to the ad-
verse side-effect profile for ERY, and the recent evidence that 
drug-drug interactions between ERY and CYP3A inhibitors 
lead to increased risk of cardiac arrhythmias and sudden cardiac 
death. In comparison to ERY and other macrolides currently 
available, AZI is a 15-membered semi-synthetic macrolide known 
to have fewer gastrointestinal side effects, better compliance and a 
lower cardiac risk profile compared to ERY.
25,32 The lower car-
diac risk profile is attributed to the lack of inhibition by AZI of 
the CYP3A isozymes, and minimal interaction with other CYP3A Treating Gastroparesis With Azithromycin
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Figure 2. Comparison of the effect of azithromycin and ery-
thromycin on gastric emptying half-times during gastric emptying 
nuclear scintigraphy. GES, gastric emptying scintigraphy.
inhibitors thus avoiding the clinically significant drug-drug inter-
actions associated with ERY.
32,33 Furthermore, in a study com-
paring ERY, clarithromycin and AZI, both ERY and clarithro-
mycin were associated with early after depolarizations and tor-
sades de pointes at lower K
+ concentrations, but AZI showed no 
association at all.
35 In addition, AZI also appeared to have the 
lowest pro-arrhythmic potential of the 3 macrolides compared.
35 
However, AZI has been implicated in QT prolongation and tor-
sades de pointes in isolated case reports of elderly patients on 
AZI.
36-38 These reports prompted a year long prospective rando-
mized control trial where patients received either AZI or placebo. 
The study concluded that while AZI was not effective for secon-
dary prevention of coronary events, no increased risk of cardiac 
events was observed in patients on AZI.
39 
In addition to the better cardiac side effect profile and fewer 
drug-drug interactions, another potential advantage of using AZI 
rather than ERY is the lower frequency of side effects reported by 
patients on AZI.
40 Frequently patients taking ERY report nau-
sea, vomiting and diarrhea. These side effects are reported much 
less frequently in patients on AZI, increasing the likelihood of 
long-term patient compliance with AZI therapy.
40 In addition to 
the lower incidence of side effects reported, AZI also has a longer 
duration of action, is absorbed well regardless of food intake, and 
has a higher bioavailability.
33,40 This higher bioavailability gives 
AZI an extensive distribution throughout the body while at the 
same time, limiting central nervous system penetration.  Finally, 
the longer half life of AZI of approximately 68 hours may permit 
once daily dosing as compared to the dosing of ERY which is re-
quired four times a day. Thus, once daily dosing in combination 
with fewer drug-drug interactions, and the lower incidence of 
side effects seen with AZI may improve patient compliance with 
this medication.  
Despite these potential benefits of AZI, this study has some 
limitations. First, our study was a retrospective analysis done in 
one tertiary care center and could not account for potential bias 
that may be associated with the generalisability of that design. In 
addition, the study was conducted with one-time administration 
of drug and did not include any assessment of symptom response. 
In addition, although we used nuclear medicine GES which is re-
garded as the gold standard test, gastric emptying times have a 
high day-to-day variability limiting oral drug testing on 2 sepa-
rate days except for large “pooled data”. The new proposed 
standard for GES involves only three data points, limiting the 
testing of IV drug response. Therefore we used same day dynam-
ic imaging with IV drug challenge. Finally, because our study on-
ly measured response in gastric emptying time after one dose of 
either IV ERY or IV AZI, the study could not account for the 
possible development of tachyphylaxis which has been observed 
both in patients on chronic ERY and in patients treated with 
short-term IV ERY.
Finally, our study has several important strengths. We use 
GES, which is the gold standard test; to both confirm the diag-
nosis of GP, and to compare responses of IV ERY and IV AZI 
on gastric emptying times. Furthermore, by demonstrating the 
equivalency of AZI and ERY in accelerating gastric emptying 
times, our study supports the possibility that AZI may be a viable 
alternative to ERY for the treatment of GP. It is also noteworthy 
that ERY is not being produced in the liquid formulation save for 
use in pediatric patients and this lack of availability of the more 
effective liquid suspension has limited use of ERY. In addition, 
in our extensive clinical experience with AZI, we have found AZI 
to be very effective for the symptomatic treatment of patients with 
GP in those who have failed on both metoclopramide and ERY 
(unpublished observations). Our results certainly justify a larger 
randomized control study with a placebo arm to further evaluate 
the efficacy and safety of AZI in the treatment of GP and for as-
sessment of gastric emptying response to IV infusion of AZI dur-
ing provocative testing with GES. Ultimately, these further stud-
ies will help to determine if AZI will prove to be an effective and 
well-tolerated treatment for GP. Jean M Larson, et al
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